Immune Checkpoint Inhibitor

An immune checkpoint inhibitor (ICI) is a cancer immunotherapy modality employing monoclonal antibodies to block negative regulatory receptors ("immune checkpoints") expressed on T lymphocytes or their cognate ligands expressed on antigen-presenting cells (APCs) and neoplastic cells. Rather than directly targeting tumor cells via cytotoxic payloads or kinase inhibition, immune checkpoint inhibitors release physiological brakes on the host immune system, enabling tumor-reactive cytotoxic CD8⁺ T lymphocytes to recognize and lyse malignant cells.

The discovery that blocking co-inhibitory T-cell receptors can eradicate established solid tumors was pioneered by James P. Allison (who demonstrated in 1996 that antibody blockade of CTLA-4 induces tumor rejection in mice, leading to the 2011 approval of ipilimumab) and Tasuku Honjo (who cloned PD-1 in 1992 and established its role as an inducible negative regulator of peripheral immunity), for which they shared the 2018 Nobel Prize in Physiology or Medicine.

The Two-Signal Requirement for T-Cell Activation

Productive activation, clonal expansion, and cytokine secretion by naive T lymphocytes require two simultaneous signals across the immunological synapse:

1. Signal 1 (Antigen Specificity): The clonotypic heterodimeric T-cell receptor (TCR) recognizes a tumor-specific neoantigen peptide presented in the groove of a major histocompatibility complex (MHC) class I (for CD8⁺ cytotoxic T cells) or MHC class II (for CD4⁺ helper T cells) molecule on an antigen-presenting cell, initiating CD3ζ and ZAP-70 tyrosine phosphorylation.
2. Signal 2 (Costimulation): The constitutively expressed costimulatory receptor CD28 on the T-cell surface binds B7-1 (CD80) and B7-2 (CD86) on mature professional dendritic cells. CD28 engagement recruits phosphatidylinositol 3-kinase (PI3K)–AKT, activates NF-κB and AP-1 transcription factors, stabilizes interleukin-2 (IL-2) mRNA, and upregulates anti-apoptotic BCL-X_L.

In the absence of Signal 2, TCR engagement alone induces T-cell anergy or deletion. Conversely, to prevent uncontrolled lymphoproliferation and autoimmune tissue destruction, activated T cells upregulate co-inhibitory checkpoint receptors—principally CTLA-4, PD-1, LAG-3, TIGIT, and TIM-3—which attenuate TCR and CD28 signaling at distinct anatomical stages of the immune response.

CTLA-4: Regulation of Lymphoid Priming

Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4 / CD152) is a structural homolog of CD28 that operates primarily during the early priming phase of naive and memory T cells in secondary lymphoid organs (draining lymph nodes). In resting naive T cells, CTLA-4 is sequestered inside intracellular clathrin-coated vesicles; upon TCR + CD28 stimulation, calcium influx triggers exocytic translocation of CTLA-4 to the immunological synapse in proportion to TCR signal strength. Furthermore, CTLA-4 is expressed constitutively at high levels on CD4⁺CD25⁺FOXP3⁺ regulatory T cells (T_reg).

CTLA-4 suppresses T-cell priming through two biophysical mechanisms:

1. Competitive Ligand Sequestration: CTLA-4 binds B7-1 (CD80) and B7-2 (CD86) as a bivalent homodimer with 10- to 20-fold higher affinity (K_d ≈ 0.2 to 0.4 μM) than monovalent CD28 (K_d ≈ 4.0 μM), outcompeting CD28 and starving the T cell of costimulatory Signal 2.
2. Trans-Endocytosis: CTLA-4 on T_reg and activated T cells captures and internalizes B7-1 and B7-2 molecules directly out of the membrane of opposing antigen-presenting cells via trans-endocytosis, targeting the stripped B7 ligands for lysosomal degradation and leaving the APC unable to costimulate bystander T cells.

Anti-CTLA-4 antibodies (ipilimumab, tremelimumab) block CTLA-4–B7 engagement, lower the activation threshold for low-affinity tumor-reactive T-cell clones, and broaden the peripheral TCR repertoire.

PD-1 / PD-L1 and Next-Generation Checkpoints (LAG-3)

Programmed Cell Death Protein 1 (PD-1 / CD279, encoded by PDCD1) regulates the effector phase of antigen-experienced T cells within peripheral non-lymphoid tissues and the tumor microenvironment (TME). When tumor-infiltrating CD8⁺ lymphocytes (TILs) recognize tumor neoantigens, they secrete interferon-gamma (IFN-γ). In a homeostatic feedback mechanism co-opted by tumors—termed adaptive immune resistance—IFN-γ binds IFNGR1/2 on tumor cells and infiltrating myeloid cells, activating the JAK1/JAK2–STAT1–IRF1 transcriptional cascade to upregulate cell-surface PD-L1 (CD274).

When PD-L1 (or PD-L2) engages PD-1 on the T cell, the cytoplasmic tail of PD-1 becomes phosphorylated on its Immunoreceptor Tyrosine-Based Inhibitory Motif (ITIM) and Immunoreceptor Tyrosine-Based Switch Motif (ITSM). The phosphorylated ITSM recruits the Src-homology 2 (SH2) domain-containing protein tyrosine phosphatase SHP-2 (PTPN11), which dephosphorylates proximal signaling intermediates—preferentially CD28 as well as CD3ζ and ZAP-70—suppressing PI3K–AKT and RAS–ERK pathways. Chronic antigen stimulation coupled with PD-1 signaling drives CD8⁺ TILs into progressive T-cell exhaustion, governed by the transcription factor TOX. Specifically, anti-PD-1/PD-L1 blockade does not reverse terminally exhausted (TCF1⁻TIM-3⁺PD-1^high) T cells; instead, it triggers a proliferative burst and effector differentiation of a stem-like progenitor-exhausted CD8⁺ T-cell subset (TCF1⁺PD-1^intSLAMF6⁺).

Co-expression of additional checkpoints such as Lymphocyte-Activation Gene 3 (LAG-3 / CD223)—which binds stable peptide–MHC class II complexes and removes the Zn²⁺-dependent kinase Lck from CD4/CD8 coreceptors—reinforces exhaustion. Dual blockade of LAG-3 (relatlimab) plus PD-1 (nivolumab) significantly prolonged progression-free survival over nivolumab monotherapy in metastatic melanoma (RELATIVITY-047).

Biomarkers of Checkpoint Inhibitor Response

Clinical response to anti-PD-1/PD-L1 monotherapy ranges from <10% in immunologically "cold" tumors (such as pancreatic ductal adenocarcinoma or microsatellite-stable colorectal cancer) to >80% in Hodgkin lymphoma and desmoplastic melanoma. Three FDA-approved companion diagnostics stratify patient selection:

1. PD-L1 Immunohistochemistry (TPS and CPS): Quantified either as the Tumor Proportion Score (TPS) (percentage of viable tumor cells showing partial or complete membrane PD-L1 staining, e.g., TPS ≥ 50% for first-line pembrolizumab monotherapy in NSCLC) or the Combined Positive Score (CPS) (number of PD-L1-staining tumor cells, lymphocytes, and macrophages divided by total viable tumor cells, multiplied by 100).
2. Mismatch Repair Deficiency and Microsatellite Instability-High (dMMR / MSI-H): Loss of DNA mismatch repair proteins (MLH1, MSH2, MSH6, or PMS2) impairs correction of polymerase slippage at repetitive microsatellite tracts, generating 10 to 100 times more somatic mutations (often >1,000 nonsynonymous mutations per exome) and immunogenic frameshift neoantigens. Following Luis Diaz and colleagues' landmark basket trials, pembrolizumab received the first tumor-agnostic FDA approval for any MSI-H/dMMR solid tumor, and neoadjuvant dostarlimab achieved a 100% clinical complete response rate without chemotherapy, radiation, or surgery in locally advanced dMMR rectal cancer.
3. Tumor Mutational Burden (TMB ≥ 10 mutations/megabase): High nonsynonymous mutational load (such as UV-induced C→T transitions in cutaneous melanoma or smoking-induced C→A transversions in NSCLC) increases the statistical probability of generating high-affinity neoepitopes presented on MHC class I.

Primary and Acquired Resistance vs. Immune-Related Adverse Events (irAEs)

Tumors evade checkpoint blockade by acquiring loss-of-function mutations in β₂-microglobulin (B2M) or HLA class I heavy chains (abolishing cell-surface MHC class I antigen presentation to CD8⁺ T cells) or truncating mutations in JAK1 or JAK2 (rendering the tumor insensitive to antiproliferative IFN-γ signaling and downregulating antigen-processing machinery TAP1/TAP2 and LMP2/LMP7).

Because CTLA-4 and PD-1 maintain peripheral self-tolerance, systemic checkpoint blockade can provoke Immune-Related Adverse Events (irAEs) affecting almost any organ system—most commonly dermatologic rash/vitiligo, autoimmune colitis/diarrhea (particularly with anti-CTLA-4), thyroiditis (hypothyroidism following transient hyperthyroidism), hypophysitis (pituitary inflammation), pneumonitis, hepatitis, and fulminant autoimmune myocarditis. Grade 3–4 irAEs are managed by withholding the ICI and administering high-dose systemic corticosteroids (prednisone or methylprednisolone 1–2 mg/kg/day) or second-line anti-TNF-α (infliximab) or mycophenolate mofetil.

Why do anti-PD-1 antibodies use an IgG4 backbone whereas ipilimumab uses an IgG1 backbone?

PD-1 is expressed directly on the tumor-specific CD8⁺ effector T cells that the therapy aims to preserve and invigorate. If an anti-PD-1 antibody used a wild-type IgG1 Fc domain, NK cells and macrophages would bind the Fc via FcγRIIIa and kill the PD-1⁺ antitumor T cells via ADCC. Therefore, pembrolizumab and nivolumab are engineered as IgG4 (S228P) antibodies with minimal FcγR engagement. Conversely, CTLA-4 is expressed at highest density on immunosuppressive intratumoral FOXP3⁺ regulatory T cells (T_reg), where IgG1-mediated ADCC depletion of T_reg cells contributes to antitumor activity.

Why are frameshift mutations in dMMR/MSI-H tumors more immunogenic than single-nucleotide point mutations?

A missense single-nucleotide variant alters only a single amino acid within an otherwise self-peptide sequence, which may bind MHC poorly or resemble tolerated self-antigens. In contrast, an insertion or deletion (indel) at a coding microsatellite shifts the ribosomal reading frame, translating a distinct C-terminal polypeptide tail downstream of the frameshift until a premature stop codon is reached—capable of generating multiple foreign neoepitopes across several HLA alleles.

How does PD-L1 interact in cis with B7-1 (CD80) on antigen-presenting cells?

In addition to binding PD-1 in trans on T cells, PD-L1 expressed on an antigen-presenting cell can bind B7-1 (CD80) in cis on the same APC membrane. Anti-PD-L1 antibodies (atezolizumab, durvalumab) disrupt both the trans PD-L1:PD-1 interaction and the cis PD-L1:B7-1 interaction, freeing B7-1 on the dendritic cell to costimulate CD28 on T cells.

1. Leach, D. R., Krummel, M. F., & Allison, J. P. (1996). "Enhancement of antitumor immunity by CTLA-4 blockade." Science, 271(5256), 1734–1736. https://doi.org/10.1126/science.271.5256.1734
2. Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992). "Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death." The EMBO Journal, 11(11), 3887–3895. https://doi.org/10.1002/j.1460-2075.1992.tb05481.x
3. Le, D. T., Uram, J. N., Wang, H., et al. (2015). "PD-1 blockade in tumors with mismatch-repair deficiency." New England Journal of Medicine, 372(26), 2509–2520. https://doi.org/10.1056/NEJMoa1500596
4. Ribas, A., & Wolchok, J. D. (2018). "Cancer immunotherapy using checkpoint blockade." Science, 359(6382), 1350–1355. https://doi.org/10.1126/science.aar4060